ETS proto-oncogene 1 (ETS1) is a downstream effector of WTAP and WTAP-regulated m6A modification leads to post-transcriptional repression of ETS1, which promotes HCC progression through the human antigen R (HuR)-ETS1-p21/p27 axis and is a potential target for HCC therapy (Chen et al., 2019c). The gene discussed is ELAVL1; the disease is hepatocellular carcinoma.